Visfatin, a potential biomarker and prognostic factor for endometrial cancer

Wenyan Tian, Yuanxi Zhu, Yingmei Wang, Fei Teng, Huiying Zhang, Guoyan Liu, Xuegong Ma, Dandan Sun, Thomas E. Rohan, Fengxia Xue

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective Visfatin, a newly discovered adipocytokine, is thought to play a role in the pathogenesis of metabolic-syndrome-related cancers. The aim of this study was to assess the clinical significance of serum levels and tissue expression of visfatin in relation to endometrial cancer (EC). Methods A total of 234 EC patients were included in this study. Serum visfatin, metabolic and anthropometric parameters were measured in EC patients and controls. Serum visfatin levels were detected using ELISA. Tissue expression of visfatin was analyzed using immunohistochemistry in tissue microarrays. The correlation between clinicopathological variables and visfatin in EC tissues and the prognostic value of visfatin for overall survival was evaluated. Results Serum levels of visfatin were significantly higher in EC patients than in controls (P < 0.05). In univariate and multivariate logistic regression models, a positive association between EC and serum visfatin, BMI, waist-to-hip ratio, diabetes, and hypertension was evident (P < 0.05). Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue (P = 0.001). Moreover, serum visfatin levels were significantly positively correlated with tissue expression of visfatin in EC patients (P < 0.05). High visfatin expression in EC tissues was significantly associated with advanced FIGO stage (P = 0.016) and myometrial invasion ≥ 1/2 (P = 0.023). The overall survival rate of EC patients was significantly higher in the group with negative visfatin expression than with positive visfatin expression (P = 0.035). Conclusions Visfatin is a potential serum biomarker and prognostic factor for EC that may indicate high risk for EC and EC progression. It may also be a novel potential therapeutic target for EC.

Original languageEnglish (US)
Pages (from-to)505-512
Number of pages8
JournalGynecologic Oncology
Volume129
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Nicotinamide Phosphoribosyltransferase
Endometrial Neoplasms
Biomarkers
Serum
Logistic Models
Adipokines
Waist-Hip Ratio

Keywords

  • Adipocytokine
  • Biomarker
  • Endometrial cancer
  • Prognostic factor
  • Visfatin

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Tian, W., Zhu, Y., Wang, Y., Teng, F., Zhang, H., Liu, G., ... Xue, F. (2013). Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecologic Oncology, 129(3), 505-512. https://doi.org/10.1016/j.ygyno.2013.02.022

Visfatin, a potential biomarker and prognostic factor for endometrial cancer. / Tian, Wenyan; Zhu, Yuanxi; Wang, Yingmei; Teng, Fei; Zhang, Huiying; Liu, Guoyan; Ma, Xuegong; Sun, Dandan; Rohan, Thomas E.; Xue, Fengxia.

In: Gynecologic Oncology, Vol. 129, No. 3, 06.2013, p. 505-512.

Research output: Contribution to journalArticle

Tian, W, Zhu, Y, Wang, Y, Teng, F, Zhang, H, Liu, G, Ma, X, Sun, D, Rohan, TE & Xue, F 2013, 'Visfatin, a potential biomarker and prognostic factor for endometrial cancer', Gynecologic Oncology, vol. 129, no. 3, pp. 505-512. https://doi.org/10.1016/j.ygyno.2013.02.022
Tian, Wenyan ; Zhu, Yuanxi ; Wang, Yingmei ; Teng, Fei ; Zhang, Huiying ; Liu, Guoyan ; Ma, Xuegong ; Sun, Dandan ; Rohan, Thomas E. ; Xue, Fengxia. / Visfatin, a potential biomarker and prognostic factor for endometrial cancer. In: Gynecologic Oncology. 2013 ; Vol. 129, No. 3. pp. 505-512.
@article{cb5e80184dba4d81b73e6d9d8e5c93d9,
title = "Visfatin, a potential biomarker and prognostic factor for endometrial cancer",
abstract = "Objective Visfatin, a newly discovered adipocytokine, is thought to play a role in the pathogenesis of metabolic-syndrome-related cancers. The aim of this study was to assess the clinical significance of serum levels and tissue expression of visfatin in relation to endometrial cancer (EC). Methods A total of 234 EC patients were included in this study. Serum visfatin, metabolic and anthropometric parameters were measured in EC patients and controls. Serum visfatin levels were detected using ELISA. Tissue expression of visfatin was analyzed using immunohistochemistry in tissue microarrays. The correlation between clinicopathological variables and visfatin in EC tissues and the prognostic value of visfatin for overall survival was evaluated. Results Serum levels of visfatin were significantly higher in EC patients than in controls (P < 0.05). In univariate and multivariate logistic regression models, a positive association between EC and serum visfatin, BMI, waist-to-hip ratio, diabetes, and hypertension was evident (P < 0.05). Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue (P = 0.001). Moreover, serum visfatin levels were significantly positively correlated with tissue expression of visfatin in EC patients (P < 0.05). High visfatin expression in EC tissues was significantly associated with advanced FIGO stage (P = 0.016) and myometrial invasion ≥ 1/2 (P = 0.023). The overall survival rate of EC patients was significantly higher in the group with negative visfatin expression than with positive visfatin expression (P = 0.035). Conclusions Visfatin is a potential serum biomarker and prognostic factor for EC that may indicate high risk for EC and EC progression. It may also be a novel potential therapeutic target for EC.",
keywords = "Adipocytokine, Biomarker, Endometrial cancer, Prognostic factor, Visfatin",
author = "Wenyan Tian and Yuanxi Zhu and Yingmei Wang and Fei Teng and Huiying Zhang and Guoyan Liu and Xuegong Ma and Dandan Sun and Rohan, {Thomas E.} and Fengxia Xue",
year = "2013",
month = "6",
doi = "10.1016/j.ygyno.2013.02.022",
language = "English (US)",
volume = "129",
pages = "505--512",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Visfatin, a potential biomarker and prognostic factor for endometrial cancer

AU - Tian, Wenyan

AU - Zhu, Yuanxi

AU - Wang, Yingmei

AU - Teng, Fei

AU - Zhang, Huiying

AU - Liu, Guoyan

AU - Ma, Xuegong

AU - Sun, Dandan

AU - Rohan, Thomas E.

AU - Xue, Fengxia

PY - 2013/6

Y1 - 2013/6

N2 - Objective Visfatin, a newly discovered adipocytokine, is thought to play a role in the pathogenesis of metabolic-syndrome-related cancers. The aim of this study was to assess the clinical significance of serum levels and tissue expression of visfatin in relation to endometrial cancer (EC). Methods A total of 234 EC patients were included in this study. Serum visfatin, metabolic and anthropometric parameters were measured in EC patients and controls. Serum visfatin levels were detected using ELISA. Tissue expression of visfatin was analyzed using immunohistochemistry in tissue microarrays. The correlation between clinicopathological variables and visfatin in EC tissues and the prognostic value of visfatin for overall survival was evaluated. Results Serum levels of visfatin were significantly higher in EC patients than in controls (P < 0.05). In univariate and multivariate logistic regression models, a positive association between EC and serum visfatin, BMI, waist-to-hip ratio, diabetes, and hypertension was evident (P < 0.05). Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue (P = 0.001). Moreover, serum visfatin levels were significantly positively correlated with tissue expression of visfatin in EC patients (P < 0.05). High visfatin expression in EC tissues was significantly associated with advanced FIGO stage (P = 0.016) and myometrial invasion ≥ 1/2 (P = 0.023). The overall survival rate of EC patients was significantly higher in the group with negative visfatin expression than with positive visfatin expression (P = 0.035). Conclusions Visfatin is a potential serum biomarker and prognostic factor for EC that may indicate high risk for EC and EC progression. It may also be a novel potential therapeutic target for EC.

AB - Objective Visfatin, a newly discovered adipocytokine, is thought to play a role in the pathogenesis of metabolic-syndrome-related cancers. The aim of this study was to assess the clinical significance of serum levels and tissue expression of visfatin in relation to endometrial cancer (EC). Methods A total of 234 EC patients were included in this study. Serum visfatin, metabolic and anthropometric parameters were measured in EC patients and controls. Serum visfatin levels were detected using ELISA. Tissue expression of visfatin was analyzed using immunohistochemistry in tissue microarrays. The correlation between clinicopathological variables and visfatin in EC tissues and the prognostic value of visfatin for overall survival was evaluated. Results Serum levels of visfatin were significantly higher in EC patients than in controls (P < 0.05). In univariate and multivariate logistic regression models, a positive association between EC and serum visfatin, BMI, waist-to-hip ratio, diabetes, and hypertension was evident (P < 0.05). Visfatin expression was significantly higher in EC tissue than in normal endometrial tissue (P = 0.001). Moreover, serum visfatin levels were significantly positively correlated with tissue expression of visfatin in EC patients (P < 0.05). High visfatin expression in EC tissues was significantly associated with advanced FIGO stage (P = 0.016) and myometrial invasion ≥ 1/2 (P = 0.023). The overall survival rate of EC patients was significantly higher in the group with negative visfatin expression than with positive visfatin expression (P = 0.035). Conclusions Visfatin is a potential serum biomarker and prognostic factor for EC that may indicate high risk for EC and EC progression. It may also be a novel potential therapeutic target for EC.

KW - Adipocytokine

KW - Biomarker

KW - Endometrial cancer

KW - Prognostic factor

KW - Visfatin

UR - http://www.scopus.com/inward/record.url?scp=84877574703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877574703&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.02.022

DO - 10.1016/j.ygyno.2013.02.022

M3 - Article

C2 - 23438672

AN - SCOPUS:84877574703

VL - 129

SP - 505

EP - 512

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -